blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3785711

EP3785711 - UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER INDUCED BY IOVERSOL,IOMEPROL OR IODIXANOL [Right-click to bookmark this link]
Former [2021/09]UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER
[2022/22]
StatusNo opposition filed within time limit
Status updated on  15.09.2023
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  07.10.2022
FormerGrant of patent is intended
Status updated on  02.06.2022
FormerExamination is in progress
Status updated on  05.11.2021
FormerRequest for examination was made
Status updated on  29.01.2021
FormerThe international publication has been made
Status updated on  02.11.2019
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Niigata University
8050, Ikarashi Ninocho
Nishi-ku
Niigata-shi
Niigata 950-2181 / JP
For all designated states
Denka Company Limited
1-1, Nihonbashi-Muromachi 2-chome
Chuo-ku
Tokyo 103-8338 / JP
[2021/09]
Inventor(s)01 / SAITO, Akihiko
c/o Graduate School of Medical and Dental Science
Medicine), Niigata University, 1-757 Asahimachi-
dori, Chuo-ku
Niigata-shi, Niigata 951-8510 / JP
02 / GOTO, Sawako
c/o Graduate School of Medical and Dental Science
Medicine), Niigata University, 1-757 Asahimachi-
dori, Chuo-ku
Niigata-shi, Niigata 951-8510 / JP
03 / HIRAYAMA, Yoshiaki
c/o Denka Seiken Co.,Ltd., 1-1, Nihonbashi-
Muromachi 2-chome, Chuo-ku
Tokyo 103-8338 / JP
04 / SEKINE, Sakari
c/o Denka Company Limited, 1-1, Nihonbashi-
Muromachi 2-chome, Chuo-ku
Tokyo 103-8338 / JP
 [2021/09]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2021/09]
Application number, filing date19794059.626.04.2019
[2021/09]
WO2019JP17963
Priority number, dateJP2018008729427.04.2018         Original published format: JP 2018087294
JP2018022503530.11.2018         Original published format: JP 2018225035
[2021/09]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019208777
Date:31.10.2019
Language:JA
[2019/44]
Type: A1 Application with search report 
No.:EP3785711
Date:03.03.2021
Language:EN
[2021/09]
Type: B1 Patent specification 
No.:EP3785711
Date:09.11.2022
Language:EN
[2022/45]
Search report(s)International search report - published on:JP31.10.2019
(Supplementary) European search report - dispatched on:EP03.05.2021
ClassificationIPC:A61K31/198, A61P13/12, A61K49/04
[2021/09]
CPC:
A61K9/0019 (EP,US); A61K31/198 (EP,US); A61K49/04 (EP,US);
A61P13/12 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/09]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERWENDUNG VON CILASTATIN ZUR HEMMUNG VON DURCH IOVERSOL,IOMEPROL ODER IODIXANOL VERURSACHTEN NIERENERKRANKUNGEN[2022/22]
English:UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER INDUCED BY IOVERSOL,IOMEPROL OR IODIXANOL[2022/22]
French:UTILISATION DE LA CILASTATINE DANS L'INHIBITION D'UN TROUBLE RÉNAL PROVOQUÉ PAR IOVERSOL,IOMEPROL OU IODIXANOL[2022/22]
Former [2021/09]VERWENDUNG VON CILASTATIN ZUR HEMMUNG VON NIERENERKRANKUNGEN
Former [2021/09]UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER
Former [2021/09]UTILISATION DE LA CILASTATINE DANS L'INHIBITION D'UN TROUBLE RÉNAL
Entry into regional phase28.10.2020Translation filed 
26.11.2020National basic fee paid 
26.11.2020Search fee paid 
26.11.2020Designation fee(s) paid 
26.11.2020Examination fee paid 
Examination procedure26.11.2020Examination requested  [2021/09]
17.08.2021Amendment by applicant (claims and/or description)
09.11.2021Despatch of a communication from the examining division (Time limit: M04)
07.03.2022Reply to a communication from the examining division
03.06.2022Communication of intention to grant the patent
05.10.2022Fee for grant paid
05.10.2022Fee for publishing/printing paid
05.10.2022Receipt of the translation of the claim(s)
Opposition(s)10.08.2023No opposition filed within time limit [2023/42]
Fees paidRenewal fee
15.12.2020Renewal fee patent year 03
29.03.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
IT09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
IE26.04.2023
LU26.04.2023
BE30.04.2023
CH30.04.2023
LI30.04.2023
[2024/26]
Former [2024/21]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
IE26.04.2023
LU26.04.2023
BE30.04.2023
CH30.04.2023
LI30.04.2023
Former [2024/12]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
LU26.04.2023
BE30.04.2023
CH30.04.2023
LI30.04.2023
Former [2024/09]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
LU26.04.2023
CH30.04.2023
LI30.04.2023
Former [2024/08]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
LU26.04.2023
Former [2024/04]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
LU26.04.2023
Former [2023/51]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/38]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/37]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/35]AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/34]AT09.11.2022
DK09.11.2022
EE09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/33]AT09.11.2022
DK09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/29]AT09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/25]AT09.11.2022
ES09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/23]AT09.11.2022
ES09.11.2022
FI09.11.2022
LT09.11.2022
LV09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
PT09.03.2023
Former [2023/22]AT09.11.2022
ES09.11.2022
FI09.11.2022
LT09.11.2022
SE09.11.2022
NO09.02.2023
PT09.03.2023
Former [2023/20]LT09.11.2022
NO09.02.2023
Documents cited:Search[A]  - ON BEHALF OF THE CONTRAST MEDIA SAFETY COMMITTEE OF EUROPEAN SOCIETY OF UROGENITAL RADIOLOGY (ESUR) ET AL, "Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines", EUROPEAN RADIOLOGY, SPRINGER, BERLIN, DE, (20110825), vol. 21, no. 12, doi:10.1007/S00330-011-2225-0, ISSN 1432-1084, pages 2527 - 2541, XP019978116 [A] 1-3 * page 2531 - page 2534 *

DOI:   http://dx.doi.org/10.1007/s00330-011-2225-0
 [A]  - YOSHIHISA HORI ET AL, "Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, (20170601), vol. 28, no. 6, doi:YOSHIHISA HORI, NOBUMASA AOKI,SHOJI KUWAHARA, ISSN 1046-6673, pages 1783 - 1791, XP009194737 [A] 1-3 * abstract *

DOI:   http://dx.doi.org/Yoshihisa Hori, Nobumasa Aoki,Shoji Kuwahara
International search[A]US2011165264  (TEJEDOR JORGE ALBERTO [ES], et al) [A] 1-3* , claims, examples *;
 [A]WO2015111666  (AJINOMOTO KK [JP], et al) [A] 1-3 * , claims, examples (Family: none) *;
 [A]KR20170086851  (IM DAI SIG [KR]) [A] 1-3 * , claims, paragraphs [0030]-[0031], [0049], example 3, fig. 3 (Family: none) *
by applicantJP2003261459
 WO2015111666
 US9216185
    - Guidelines on the Use of Iodinated Contrast Media in Patients with Kidney Disease 2012, JSN, JRS and JCS Joint Working Group, pages 50 - 79
    - MARZOLO et al., Biological Research, (20110000), vol. 44, pages 89 - 105
    - CHRISTENSEN et al., Nature Reviews Molecular Cell Biology, (20020000), vol. 3, pages 258 - 268
    - OYAMA et al., Laboratory Investigation, (20050000), vol. 85, pages 522 - 531
    - NORDBY et al., Scanning Microsc, (19900000), vol. 4, pages 651 - 666
    - TANAKA et al., BMJ Open, (20140000), vol. 4, page e004407
    - MORIYAMA et al., Am JRespir Crit Care Med, (20070000), vol. 176, pages 70 - 77
    - ZHANG et al., Kidney Int, (20080000), vol. 73, pages 608 - 614
    - ORLANDO et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 6698 - 6702
    - DE et al., Diabetes, (20170000), vol. 66, pages 1391 - 1401
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.